UK: IP Bulletin - June 2014

Last Updated: 3 July 2014
Article by Ian Wood

Welcome to the June edition of "IP Bulletin" – the intellectual property law update from Charles Russell's Intellectual Property team.

The Bulletin details some recent important cases and key developments.


UK appeal stayed pending outcome of EPO central amendment applications: Samsung Electronics Co Ltd v Apple Retail UK Ltd & Other [2014] EWCA Civ 250


The Court of Appeal recently stayed Samsung's appeal against a finding of invalidity of two of its mobile 'phone patents, pending the outcome of Samsung's applications for central amendment of those patents at the European Patent Office ("EPO"). The Court of Appeal said that Samsung's application for a stay was not an abuse of the court process because UK legislation allowed for parallel proceedings in both the national courts and the EPO. In addition, the central amendment application was expected to conclude soon and a refusal of the stay might have resulted in the UK appeal proceeding on what may turn out to have been a false basis, resulting in wasted costs and time for the parties.

The decision to stay the appeal leaves the parties in a state of flux, facing uncertainty until the outcome of EPO procedures is known. Additionally, many interested parties may find it highly unsatisfactory that, if the amendments are allowed, the Court of Appeal will be the first UK court to consider the amended patents following the EPO's decision. The Court of Appeal has already made clear that the appeal in respect of both patents will not be heard until the EPO's decision is known in relation to both central amendment applications (the EPO ruled recently on one of the patents and a decision is expected shortly on the other). The Court of Appeal has said it is appropriate in the circumstances that there should be a single appeal hearing in relation to both patents.

Samsung Electronics Co Ltd v Apple Retail UK Ltd and another [2014] EWCA Civ 250, 11 March 2014


In this patent dispute, Samsung brought patent infringement proceedings against Apple in the UK alleging that Apple infringed three of Samsung's patents concerning mobile 'phones. (Only two of the patents were at issue in the appeal.) In the High Court in March 2013, Floyd J held that neither of the two Samsung patents was entitled to its claimed priority date and that each was invalid (by reason of intervening prior art). He also held that even if the patents had been entitled to their claimed priority dates, both patents would have been invalid for obviousness. Samsung appealed this decision.

Samsung also filed applications (in November 2013) at the EPO to amend the two patents at issue (the "central amendment applications") .

Samsung then applied to adjourn the UK appeal pending determination of the central amendment applications.


The Court of Appeal agreed to grant Samsung's application to stay the appeal from the High Court decision of March 2013, pending a decision of the EPO of Samsung's application for central amendment of the patents.

The Court of Appeal made the following key points in its judgment:

  • Samsung's central amendment applications were proceeding and likely to be concluded in the relatively near future (and very likely before final disposition of the Court of Appeal proceedings);
  • any application made by Samsung after the trial to amend the patents (under s75 Patents Act 1977) would very likely have been refused in the exercise of the court's discretion (following Nikken Kosakushko Works v Pioneer Trading Co [2005] EWCA Civ 906 and Nokia GmbH v IPCom & Co KG [2011] EWCA Civ6);
  • the pursuit of the central amendment applications is not itself an abuse of the process of the court (it is permitted by the European Patent Convention, the implementing regulations and the Patents Act 1977) – it was therefore not an abuse of process for Samsung to make and pursue its central amendment applications. Support for this conclusion may be derived from the Supreme Court's decision in Virgin Atlantic Airways Ltd v Zodiac Seats UK Ltd [2013] UKSC 46;
  • the central amendment applications may or may not be successful. The EPO's decision (if the EPO grants the applications) would be effective in every designated state, and the patents would be deemed to have been in their amended form from grant;
  • it was not suggested that an adjournment would in and of itself cause Apple any significant prejudice; and
  • a refusal of the adjournment might have resulted in the appeal proceeding on what may turn out to have been a false basis with the consequential waste of costs and time that would entail.

Following the Court of Appeal's decision, the parties shortly found themselves back in court. The EPO had ruled on one of the patents, allowing the amendment, but indicated that a final determination in respect of the other patent would take a further few months. Samsung submitted that the appeal in respect of the first patent should not be delayed pending the EPO's decision concerning the second patent but the Court of Appeal decided that there should be a single appeal hearing on both patents when the outcome of the EPO's decision is known. Samsung had commenced proceedings against Apple for infringement of both patents in a single action, there were legal issues common to both cases and single legal teams were engaged on the appeal. In the circumstances, the court said it was appropriate that there should be a single appeal hearing in relation to both patents.

Samsung Electronics Co Ltd v Apple Retail UK Ltd and another [2014] EWCA Civ 376, 1 April 2014

New technology transfer block exemption and guidelines – effective from May 2014


The European Commission has adopted a new technology transfer block exemption regulation and guidelines on the application of Article 101 of the Treaty on the Functioning of the European Union ("TFEU") to technology transfer agreements.

The new arrangements (which replace existing arrangements in place since 2004) will be effective from May 2014 and will provide, for technology transfer agreements, an automatic exemption from the prohibition on anti-competitive agreements set out in Article 101. A transitional period lasting one year will be available to protect existing agreements. It will therefore be advisable to reassess existing agreements to check if they require amendment in order to continue to comply with EU competition law after the transitional period.


Technology transfer agreements are licensing agreements where one party authorises another party to use the licensor's patents, know how or software for the production of goods or services. The block exemption helps businesses understand whether agreements to which they are a party could be held invalid for breaching EU competition law if particular clauses are included. (There is a risk of significant fines for companies breaching competition law.)

What are the changes?

The main changes concern:

  • a new test for assessing when provisions relating to the licensing of other intellectual property rights and the purchase of products by the licensee are covered by the block exemption;
  • a change to the treatment of certain passive sales restrictions;
  • the removal of all exclusive grant back obligations from the scope of the block exemption;
  • changes to the treatment of clauses allowing a licensor to terminate if the licensee challenges the validity of the licensed intellectual property rights; and
  • clarifications of the Commission's approach to settlement agreements.

For a transitional period lasting one year, agreements block exempted under the old rules will continue to receive protection. It will therefore be advisable to review existing agreements during the transitional period to check if they require amendment in order to continue to comply with EU competition law when the transitional period expires.

IP/14/229, MEMO/14/208

Unitary Patent Court - Update

There have been a few recent developments concerning the introduction of the new Unitary Patent Court ("UPC"). The most important recent development is that the UPC will not be operational until the end of 2015 at the earliest. Most of the other developments are of an administrative nature.

The fifth meeting of the Preparatory Committee for the Unified Patent Court (UPC) on 18 March 2014 agreed that the UPC will not be operational until the end of 2015 at the earliest.

In addition, a dedicated training centre for judges for the Unified Patent Court was officially opened on 13 March 2014 in Budapest.

The latest draft Rules of Procedure for the Unified Patent Court (UPC) have been published for information only, taking into account comments received during the public consultation on the previous (15th) draft. The Legal Group of the Preparatory Committee will now examine the draft set of rules at the level of participating EU member states. Any comments should be submitted at the oral hearing planned to be held by the Legal Group in the course of this year, which will seek input of users on all suggested amendments to the text since the written consultation.

Sweden, Lithuania, Latvia and Estonia have agreed on the creation of a regional division of the Unified Patent Court (UPC). This is the first agreement by a group of member states who are signatories to the UPC Agreement to set up a regional division; there is expected to be at least one more, for the Benelux countries (Belgium, Netherlands and Luxembourg).

The EPO has published the results of a study on the effects (advantages and disadvantages) of the UPC regime.

The main concerns raised relate to the level of fees for the Unitary Patent itself, which have not yet been decided, and the costs (also unknown) and procedural uncertainties of the UPC.

Hospira UK Ltd v Genentech Inc. - High Court finds two patents relating to Herceptin (the breast cancer drug) invalid


This decision by the High Court, finding Genentech's Herceptin patents invalid, paves the way (subject to an appeal by Genentech) for Hospira to launch its generic version of the breast cancer treatment when Genentech's Herceptin SPC expires in July 2014.

Herceptin is one of the best-selling drugs in the world. Not only has it been of benefit to many patients and contributed much towards progress in the treatment of breast cancer, Herceptin has also generated huge profits – 49 billion Swiss Francs of sales - for the Roche group (profits now within reach of generic companies). Genentech's protection for the branded drug in the US expires in 2019, providing further opportunity for generics.

The case illustrates that care needs to be taken when pursuing follow-on protection for inventions. It is clear from the present decision that trying to extend protection for a successful branded product such as Herceptin is likely to raise issues of obviousness, based upon prior art previously disclosed at the time of the application for protection / regulatory approval of the branded product.


Genentech's basic Herceptin patent extended by SPC is due to expire on 28 July 2014. The present action was brought by a generic drug company (Hospira) to clear entry to the market on expiry of the basic patent.

Genentech (part of the Swiss pharma company Roche) had a number of follow-on patents, two of which (EPs '115 and '455) Hospira might have infringed on launching a generic version of the drug. One patent ('115) related to a dosage regime, the other ('455) to a method of purification of the active component.

Hospira said that the '115 patent claims were invalid (obvious over the state of the art at the earliest priority date. The key item of prior art was a US FDA label for Herceptin published when Herceptin was approved by the FDA) and that the '455 claims were invalid (because they lacked novelty over a previous Genentech Patent Co-operation Treaty application (the "Andya" prior art) and that the invention was obvious, relying in this respect on some slides presented at a conference in 1996 (the "Waterside" prior art)).


Birss J held that the '115 claims were obvious (over the FDA label) and if not invalid for obviousness, were invalid for insufficiency (based on the information in the patent, read in the light of common general knowledge) and not entitled to the claimed priority. He also held the '455 claims lacked novelty over Andya and lacked inventive step (over Waterside).

Hospira had applied for a declaration of non-infringement which Birss J granted (on the basis that Hospira's generic composition fell outside the scope of Genentech's claims). A generic version of the breast cancer treatment drug is likely to be available in July 2014 (subject to Genentech appealing the decision).

Hospira UK Ltd v Genentech Inc [2014] EWHC 1094 (Pat), 10 April 2014

To read this Bulletin in full, please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Ian Wood
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.